Abstract | CONTEXT: METHODS: Eight patients (median age 14.5 years), who had more than 2% minimal residual disease (MRD) by flow cytometry (MRD flow), received gemtuzumab 3 mg/m² on days 1, 4, 7, associated with cytarabine 2000 mg/m² and fludarabin 30 mg/m² on days 1 to 5. RESULTS: Six patients achieved complete remission (CR) (blast count morphology ≤5 × 10-2 , CR-MRD flow <1 × 10-3 for four patients). Five patients received a second course. We observed 11 episodes of febrile neutropenia, including 6 septicemias without complication. There was no fungal infection or toxic death. Two patients received granulocyte colony stimulating factor. One patient had partial platelet recovery; one, prolonged pancytopenia. All patients received hematopoietic stem cell transplantation (HSCT). We observed five mild-to-severe sinusoidal obstruction syndromes during HSCT procedures, particularly in patients who did not receive defibrotide prophylaxis. At the date of last contact (median follow-up: 58 months; range: 22-78), six patients were in continuous CR with negative MRD. Two patients died of post-HSCT relapse. CONCLUSION: FLA-GO is a good salvage regimen for pediatric refractory AML, with significant but acceptable toxicity. HSCT is mandatory to achieve sustained CR in these patients.
|
Authors | Mathilde Penel-Page, Adriana Plesa, Sandrine Girard, Alice Marceau-Renaut, Cécile Renard, Yves Bertrand |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 67
Issue 6
Pg. e28305
(06 2020)
ISSN: 1545-5017 [Electronic] United States |
PMID | 32307866
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | © 2020 Wiley Periodicals, Inc. |
Chemical References |
- Cytarabine
- Gemtuzumab
- Vidarabine
- fludarabine
|
Topics |
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Child
- Combined Modality Therapy
- Cytarabine
(administration & dosage)
- Drug Resistance, Neoplasm
- Female
- Follow-Up Studies
- Gemtuzumab
(administration & dosage)
- Hematopoietic Stem Cell Transplantation
(mortality)
- Humans
- Leukemia, Myeloid, Acute
(pathology, therapy)
- Male
- Neoplasm Recurrence, Local
(pathology, therapy)
- Prognosis
- Retrospective Studies
- Salvage Therapy
- Survival Rate
- Vidarabine
(administration & dosage, analogs & derivatives)
|